Compounds > aspirin
Page last updated: 2024-10-23

aspirin and ST Elevated Myocardial Infarction

aspirin has been researched along with ST Elevated Myocardial Infarction in 93 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI."9.41Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021)
"In patients with acute coronary syndrome treated with dual antiplatelet therapy, ticagrelor concentration >694."8.31The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023)
"The benefits of short versus long-term dual antiplatelet therapy (DAPT) based on the third generation P2Y12 antagonists prasugrel or ticagrelor, in patients with acute coronary syndromes treated with percutaneous coronary intervention remain to be clearly defined due to current evidences limited to patients treated with clopidogrel."7.96Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020)
"The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)."7.91The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019)
"There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease."7.85Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017)
"We compared 482 STEMI patients who received aspirin, ticagrelor, and UFH loading in a non-PCI capable spoke hospital before transfer (NPHT) versus 227 prehospital triage setting (PTS) STEMI patients who received in-ambulance aspirin, followed by ticagrelor and UFH in the hub catheterization laboratory."5.62The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention. ( Bérubé, S; Couture, ÉL; d'Entremont, MA; Desgagnés, N; Huynh, T; Karzon, A; Laferrière, C; Lepage, S; Nguyen, M; Verreault-Julien, L, 2021)
"In a real-world population with ACS, DAPT with ticagrelor or prasugrel are associated with increased bleeding compared with DAPT with clopidogrel."5.51Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe ( Harris, J; Johnson, TW; Lasserson, D; Loke, YK; Mahadevan, K; Mumford, A; Pouwels, K; Pufulete, M; Reeves, BC, 2022)
"Chest pain recurrence was defined as the first revisit to the emergency room with angina."5.48Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018)
"At day 4 after STEMI, HPR-aspirin was found in 26% patients and HPR-P2Y12i in 7%."5.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
"Dual antiplatelet therapy with aspirin and P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) has been shown to be associated with better outcomes."5.41Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis. ( Aguiar, C; Albuquerque, F; Almeida, M; Ferreira, J; Gomes, DA; Mendes, M; Presume, J; Uva, MS, 2023)
"The aim of this study was to investigate the safety and efficacy of dabigatran dual therapy (110 or 150 mg twice daily, plus clopidogrel or ticagrelor) versus warfarin triple therapy in patients with atrial fibrillation and STEMI."5.41Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. ( Bhatt, DL; Cannon, CP; Gabor Kiss, R; Hohnloser, SH; Leiva, O; Lip, GYH; Miede, C; Navarro Estrada, J; Nickenig, G; Nordaby, M; Oldgren, J; Ongen, Z; Oude Ophuis, T; Steg, PG; Ten Berg, JM; Zeymer, U, 2021)
"In STEMI patients with HPR, identified by vasodilator stimulated phosphoprotein (VASP)-determined PFT, switching clopidogrel to ticagrelor could significantly improve 1-year clinical outcomes without increasing the risk of bleeding."5.34Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study. ( Gao, L; Geng, L; Guo, W; Li, H; Li, J; Wan, Q; Wang, X; Wang, Y; You, J; Zhang, Q, 2020)
" Methods and Results Healthy volunteers and patients with stable coronary artery disease receiving aspirin received escalating doses of RUC-4 or placebo in a sentinel-dose, randomized, blinded fashion."5.34First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction. ( Bentur, O; Carlson, M; Coller, BS; DeMaria, AN; Garza, D; Gibson, CM; Henry, TD; Kereiakes, DJ; Martin, LH; Meek, T; Midkiff, J; Mueller, M; Seng Yue, C, 2020)
"In the ATLANTIC (Administration of Ticagrelor in the catheterization laboratory or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery) trial the early use of aspirin, anticoagulation, and ticagrelor coupled with very short medical contact-to-balloon times represent good indicators of optimal treatment of ST-elevation myocardial infarction and an ideal setting to explore which factors may influence coronary reperfusion beyond a well-established pre-hospital system."5.30Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial. ( Bolognese, L; Cantor, WJ; Cequier, A; Chettibi, M; Diallo, A; Fabris, E; Goodman, SG; Hamm, CW; Hammett, CJ; Huber, K; Janzon, M; Kerneis, M; Lapostolle, F; Lassen, JF; Merkely, B; Montalescot, G; Storey, RF; Ten Berg, JM; Tsatsaris, A; van 't Hof, A; Vicaut, E; Zeymer, U, 2019)
" Ticagrelor was more effective than clopidogrel in TAPT; however, when using the combination of aspirin, ticagrelor, and tirofiban, close monitoring is required for possible bleeding complications."5.24Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study. ( Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y, 2017)
"Aspirin loading (chewable or intravenous) as soon as possible after presentation is a class I recommendation by current ST elevation myocardial infarction (STEMI) guidelines."5.22Do We Really Need Aspirin Loading for STEMI? ( Alam, M; Atar, D; Birnbaum, Y; Davidson, SM; Jneid, H; Kitakaze, M; Uretsky, BF; Ye, R; Yellon, DM, 2022)
"In patients with acute coronary syndrome treated with dual antiplatelet therapy, ticagrelor concentration >694."4.31The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study. ( Guo, BY; Hao, J; Liu, JM; Ren, JL; Sun, YQ; Wang, CC; Yang, XL; Zhang, XR; Zhao, JJ; Zhao, Q, 2023)
"Coronary artery bypass grafting and conservatively managed acute coronary syndrome: aspirin (reference) compared with aspirin and clopidogrel."4.31Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies. ( Benedetto, U; Doble, B; Harris, J; Hopewell-Kelly, N; Johnson, T; Lasserson, D; Loke, Y; Mahadevan, K; Mumford, A; Pithara, C; Pouwels, KB; Pufulete, M; Redwood, S; Reeves, B; Rogers, C; Sterne, J; Wordsworth, S, 2023)
"We investigated the effects of glenzocimab (monoclonal antibody Fab fragment) using blood from healthy donors and patients with acute coronary syndrome treated with aspirin and ticagrelor."4.31Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy. ( Alenazy, FO; Brady, P; Connolly, DL; Harbi, MH; Hargreaves, O; Harrison, P; Jandrot-Perrus, M; Kalia, N; Kavanagh, DP; Kirchhof, P; Mangin, PH; Nicolson, PLR; Price, J; Slater, A; Thomas, MR; Tiwari, A; Watson, SP, 2023)
"The benefits of short versus long-term dual antiplatelet therapy (DAPT) based on the third generation P2Y12 antagonists prasugrel or ticagrelor, in patients with acute coronary syndromes treated with percutaneous coronary intervention remain to be clearly defined due to current evidences limited to patients treated with clopidogrel."3.96Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry. ( Abu-Assi, E; Alexopoulos, D; Ariza-Solé, A; Autelli, M; Bertaina, M; Blanco, PF; Boccuzzi, G; Bongiovanni, F; Cequier, A; Cerrato, E; D'Ascenzo, F; Dominguez-Rodriguez, A; Durante, A; Fernández, MC; Fioravanti, F; Gaita, F; Gallo, D; Garay, A; Gili, S; Grosso, A; Iñiguez-Romo, A; Kinnaird, T; Lüscher, TF; Magnani, G; Manzano-Fernández, S; Montabone, A; Morbiducci, U; Omedè, P; Paz, RC; Pousa, IM; Quadri, G; Queija, BC; Raposeiras-Roubin, S; Rinaldi, M; Rognoni, A; Taha, S; Templin, C; Valdés, M; Varbella, F; Velicki, L; Xanthopoulou, I, 2020)
"The aim of this study is to investigate the impact of ticagrelor as compared to clopidogrel based dual antiplatelet therapy (DAPT) during post-discharge management on the incidence of left ventricular (LV) thrombus in patients with first acute anterior ST elevation myocardial infarction (STEMI)."3.91The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction. ( Altındağ, R; Altıntaş, B; Baysal, E; Bilge, Ö; Burak, C; Ede, H; Karahan, MZ; Öztürk, Ö; Tanboğa, İH; Yaylak, B, 2019)
"Between January 2012 and January 2017, 24 patients undergoing coronary angiography for stable coronary disease (7 cases) or acute coronary syndromes (non-ST-segment myocardial infarction [NSTEMI; 8 cases], STEMI [9 cases]) underwent aspirin desensitization having reported previous reactions to aspirin."3.91Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience. ( Austin, D; Bolton, S; Callaghan, S; Carter, J; de Belder, MA; Hall, JA; Jackson, M; Muir, DF; Stapleton, J; Sutton, AGC; Swanson, N; Williams, PD; Wright, RA, 2019)
"Among 1469 patients with incident ST-elevation myocardial infarction (STEMI, 14%) or non-STEMI (86%), 390 patients were prescribed DAPT, 549 aspirin only, and 530 clopidogrel only."3.88Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction. ( Chan, KA; Lai, CL; Lai, HY; Lai, MS; Lin, TT; Yang, YY, 2018)
"There are limited data on aspirin (ASA) desensitization for patients with coronary artery disease."3.85Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease). ( Angiolillo, DJ; Anzuini, A; Bianco, M; Bossi, I; Capodanno, D; Colombo, P; Dossena, C; Iorio, A; Leonardi, S; Lettieri, C; Musumeci, G; Pozzi, R; Rigattieri, S; Rossini, R; Senni, M, 2017)
"A total of 32 STEMI patients were randomized (16 LA, 16 aspirin)."3.30Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial. ( Bernardo, E; Fernández-Ortiz, A; Gómez-Polo, JC; Jiménez, JJ; Martín-Asenjo, R; Moreno, G; Ortega-Pozzi, MA; Pérez-Villacastín, J; Vilacosta, I; Vivas, D, 2023)
" In conclusion, treatment with low-dose IC TNK appears safe and well tolerated during PPCI."2.94Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49). ( Bainey, KR; Devireddy, C; Gibson, CM; Gopalakrishnan, L; Grip, L; Guo, J; Kazziha, S; Kumar, V; Marshall, JJ; Mavromatis, K; Pinto, D; Singh, P; Stouffer, GA, 2020)
"4,110 patients were treated for STEMI, mean age 62."2.90ST-Elevation Acute Myocardial Infarction in Australia-Temporal Trends in Patient Management and Outcomes 1999-2016. ( Aliprandi-Costa, B; Brieger, D; D Souza, M; French, J; Kritharides, L; Morgan, L; Ranasinghe, I; Snell, LC, 2019)
"The presence of carotid atherosclerosis accompanied by coronary artery disease is associated with poor prognosis."2.87The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. ( Bulut, U; Demir, AR; Kalayci, B; Karakurt, H; Karakurt, ST; Serbest, NG; Somuncu, MU, 2018)
"Among 3,602 patients with STEMI who were enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial, all ischemic and bleeding events, including recurrent events, were classified according to the timing of their occurrence as acute (≤24 h after PCI), subacute (1 day to 30 days), and late (30 days to 1 year)."2.84Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. ( Brener, SJ; Dangas, GD; Deliargyris, EN; Généreux, P; Giustino, G; Kirtane, AJ; Mehran, R; Pocock, SJ; Prats, J; Redfors, B; Stone, GW, 2017)
"Ticagrelor is a direct-acting P2Y12 inhibitor and, unlike clopidogrel and prasugrel, does not require metabolic activation."2.84Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial. ( Abu-Much, A; Asher, E; Barbash, I; Beigel, R; Chernomordik, F; Elian, D; Fefer, P; Guetta, V; Katz, M; Matetzky, S; Mazin, I; Narodistky, M; Regev, E; Sabbag, A; Segev, A; Tal, S, 2017)
"We compared the data from the Henan STEMI survey conducted in 2011-2012 ( n = 1548, a cross-sectional study) and the Henan STEMI registry in 2016-2018 ( n = 4748, a multicenter, prospective observational study)."1.91Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018. ( Cheng, Q; Gao, C; Hu, D; Li, M; Qi, D; Wang, S; Wang, X; Zhang, Y; Zhu, Z, 2023)
"In selected patients with STEMI and aspirin hypersensitivity, particularly in the suspect of suboptimal enteric absorption of P2Y12 inhibitors, the use of cangrelor until aspirin desensitization is completed can be considered; bridge therapy to desensitization with glycoprotein IIb/IIIa inhibitors can be considered on a case by case basis, despite the scarce supporting evidence - bridge therapy with indobufen is not recommended due to the limited literature data."1.72[Management of ST-elevation myocardial infarction in a patient with aspirin hypersensitivity without oral P2Y12 inhibitors]. ( Bianco, M; Biolè, C; Cerrato, E; Destefanis, P; Luciano, A; Montagna, L; Spirito, A, 2022)
" The effectiveness outcome was major adverse cardiovascular events (MACE) defined as a composite of recurrent myocardial infarction, repeat revascularization, stroke, or cardiovascular death at 12 months."1.72Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study. ( Bhatt, DL; Butt, JH; Christensen, MK; Fosbøl, EL; Gislason, G; Godtfredsen, SJ; Jørgensen, SH; Kragholm, KH; Køber, L; Leutscher, P; Pareek, M; Sessa, M; Torp-Pedersen, C, 2022)
"In patients with STEMI undergoing pPCI the rate of nonresponsiveness to ASA was not different comparing an oral 'noncoated' loading dose of ASA with an intravenous bolus injection of lysine acetylsalicylate."1.62Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. ( Crimi, G; Ferlini, M; Ferrario, M; Klersy, C; Leonardi, S; Mandurino Mirizzi, A; Marinoni, B; Montalto, C; Oltrona Visconti, L; Repetto, A; Somaschini, A, 2021)
"Treatment with ticagrelor on discharge was associated with improved survival rates during 4 years of follow-up."1.62Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. ( Boasi, V; Cannarile, P; Cattunar, S; Gomez, L; Mascelli, G; Perri, D; Pingelli, N; Sanchez, F; Tacchi, C; Vercellino, M, 2021)
"We compared 482 STEMI patients who received aspirin, ticagrelor, and UFH loading in a non-PCI capable spoke hospital before transfer (NPHT) versus 227 prehospital triage setting (PTS) STEMI patients who received in-ambulance aspirin, followed by ticagrelor and UFH in the hub catheterization laboratory."1.62The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention. ( Bérubé, S; Couture, ÉL; d'Entremont, MA; Desgagnés, N; Huynh, T; Karzon, A; Laferrière, C; Lepage, S; Nguyen, M; Verreault-Julien, L, 2021)
"In patients with STEMI ischemia, giving nitroglycerin 10 min after aspirin dosing (compared to giving them simultaneously) leads to a greater than 20% reduction in need for additional nitroglycerin, a greater than 7% decrease in subjective pain experienced by the patient and reduced need for additional opioids."1.62The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome. ( Todoroski, KB, 2021)
"In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic."1.56Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic. ( Huang, Z; Lin, Y; Su, H; Wang, N; Zhang, M, 2020)
"Mortality in patients with STEMI-associated cardiogenic shock (CS) is increasing."1.56Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic Shock. ( Ellis, SG; Huded, CP; Kapadia, SR; Khot, UN; Krishnaswamy, A; Krittanawong, C; Kumar, A; Lincoff, AM; Menon, V; Reed, GW; Young, LD; Zhou, L, 2020)
" We took into account several criteria like statin dosage (low versus high intensity) and presence of contraindication for consideration of optimal therapy."1.56Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study. ( Bruggmann, C; Fesselet, R; Gex-Fabry, M; Iglesias, JF; Sadeghipour, F; Vogt, P; Voirol, P, 2020)
"Compared to medication therapy, PCI for STEMI delayed beyond 12 h after the onset of symptoms can better reduce mortality and the incidence of MACEs."1.51Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study. ( Ma, YT; Xie, X; Xiu, WJ; Yang, HT; Zheng, YY, 2019)
"ST elevation myocardial infarction (STEMI) is a time-dependent clinical emergency."1.51Improving the prehospital management of ST elevation myocardial infarction: a national quality improvement initiative. ( Al Shaikh, L; Castle, N; Howard, I; Owen, R, 2019)
"A retrospective analysis of STEMI patients from 18 hospitals across Malaysia contributing to the Malaysian National Cardiovascular Database-acute coronary syndrome) registry (NCVD-ACS) year 2006-2013."1.51In-hospital mortality of cardiogenic shock complicating ST-elevation myocardial infarction in Malaysia: a retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry. ( Hadi, MF; Hafidz, MI; Ismail, MD; Venkatason, P; Wan Ahmad, WA; Zubairi, YZ; Zuhdi, ASM, 2019)
"In patients undergoing p-PCI for STEMI, MEA platelet function observed in coronary arteries was consistent with peripheral artery blood's independently of the antiplatelet drug used."1.48On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). ( Al Mamary, A; Campello, E; Dalla Valle, F; Maggiolo, S; Napodano, M; Piazza, D; Simioni, P; Spiezia, L, 2018)
"Chest pain recurrence was defined as the first revisit to the emergency room with angina."1.48Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome. ( Lee, Y; Park, HC; Shin, J, 2018)
"Implementation of a regional STEMI system was associated with lower mortality and higher use of evidence-based therapies."1.48Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST). ( Argôlo, FC; Ballalai, CS; Barbosa, LS; Câmara, SF; Carvalho, LGM; De Lúcia, CV; Feitosa Filho, GS; Filgueiras Filho, NM; Granger, CB; Guimarães, PO; Lopes, RD; Newby, LK; Novais, VO; Paiva Filho, IM; Rios, MNO; Solla, DJF; Teixeira, LS, 2018)
" Major adverse cardiac and cerebrovascular events (MACCE) [death, myocardial infarction (MI), stroke, and unplanned reintervention] and thrombolysis in myocardial infarction (TIMI) bleeding (major/minor) were registered during hospitalization and follow-up."1.48Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. ( Dannenberg, L; Dimitroulis, D; Golabkesh, M; Helten, C; Jung, C; Kelm, M; Knoop, B; Naguib, D; Pöhl, M; Polzin, A; Zeus, T, 2018)
"Five hundred eighty-six STEMI patients undergoing primary percutaneous coronary intervention were evaluated including 116 prior aspirin users."1.48Are Prior Aspirin Users With ST-Elevation Myocardial Infarction at Increased Risk of Adverse Events and Worse Angiographic Features? ( Geraiely, B; Mortazavi, SH; Poorhosseini, H; Sadeghian, S; Sattarzadeh Badkoubeh, R, 2018)
"In the STEMI population, the IMR following coronary intervention appears to predict LVEF."1.48Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction. ( Adams, H; Ashokkumar, S; Burns, AT; Judkins, C; La Gerche, A; Layland, J; MacIsaac, AI; Palmer, S; Whitbourn, RJ; Williams, PD; Wilson, AM, 2018)
"Patients with STEMI undergoing PPCI within 12hours of symptoms onset were included prospectively."1.46Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. ( Aitmokhtar, O; Azaza, A; Azzouz, A; Benamara, S; Benathmane, T; Benkhedda, S; Bonello, L; Bouzid, A; Hamza, O; Harbi, F; Kara, M; Monsuez, JJ; Paganelli, F; Saidane, M; Seddiki, S; Sik, A, 2017)
"Late presenters STEMI patients present a worse risk profile and prognosis compared with patients who arrive less than 12 h from onset of symptoms."1.46Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters. ( Cerrato, E; Chinaglia, A; Ferro, S; Forno, D, 2017)
"Longitudinal analyses of the STEMI subgroup are reported."1.46A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012. ( Devlin, G; Elliott, JM; Ellis, CJ; French, JK; Gamble, GD; Hamer, A; Mann, S; Matsis, P; Richards, M; Troughton, R; Wang, TK; White, HD; Williams, MJ, 2017)
"Hemorrhagic stroke is not the only complication of thrombolysis, ischemic stroke can occur even if it is an extremely rare complication."1.46Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports. ( Arous, S; Bentaoune, T; El Ghali Benouna, M; Habbal, R; Haboub, M, 2017)
"At day 4 after STEMI, HPR-aspirin was found in 26% patients and HPR-P2Y12i in 7%."1.43High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016)
" The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations."1.43The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study. ( Bolek, T; Fedor, M; Fedorová, J; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016)

Research

Studies (93)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's52 (55.91)24.3611
2020's41 (44.09)2.80

Authors

AuthorsStudies
Todoroski, KB1
Bianco, M2
Biolè, C1
Spirito, A1
Destefanis, P1
Luciano, A1
Montagna, L1
Cerrato, E3
Asanuma, H1
Kitakaze, M2
Ye, R1
Jneid, H1
Alam, M1
Uretsky, BF1
Atar, D1
Davidson, SM1
Yellon, DM1
Birnbaum, Y1
Fabris, E2
Menzio, S1
Gregorio, C1
Pezzato, A1
Stolfo, D1
Aleksova, A1
Vitrella, G1
Rakar, S1
Perkan, A1
Van't Hof, AW1
Sinagra, G1
Godtfredsen, SJ1
Kragholm, KH1
Leutscher, P1
Jørgensen, SH1
Christensen, MK1
Butt, JH1
Gislason, G1
Køber, L2
Fosbøl, EL1
Sessa, M1
Bhatt, DL3
Torp-Pedersen, C1
Pareek, M1
Pufulete, M2
Harris, J2
Pouwels, K1
Reeves, BC1
Lasserson, D2
Loke, YK1
Mumford, A2
Mahadevan, K2
Johnson, TW1
Moledina, SM1
Mannan, F1
Weight, N1
Alisiddiq, Z1
Elbadawi, A1
Elgendy, IY1
Fischman, DL1
Mamas, MA2
Vivas, D2
Jiménez, JJ2
Martín-Asenjo, R2
Bernardo, E2
Ortega-Pozzi, MA2
Gómez-Polo, JC2
Moreno, G2
Vilacosta, I2
Pérez-Villacastín, J2
Fernández-Ortiz, A2
Shekhar, AC2
Larkin, A2
Fisher, B2
Mann, NC2
Yao, Y1
Li, X2
Wang, Z2
Xu, S1
Lv, Q1
Wang, CC1
Zhao, Q1
Guo, BY1
Hao, J1
Zhao, JJ1
Ren, JL1
Sun, YQ1
Zhang, XR1
Yang, XL1
Liu, JM1
Pouwels, KB1
Johnson, T1
Sterne, J1
Pithara, C1
Reeves, B1
Benedetto, U1
Loke, Y1
Doble, B1
Hopewell-Kelly, N1
Redwood, S1
Wordsworth, S1
Rogers, C1
Presume, J1
Gomes, DA1
Ferreira, J1
Albuquerque, F1
Almeida, M1
Uva, MS1
Aguiar, C1
Mendes, M1
Alenazy, FO1
Harbi, MH1
Kavanagh, DP1
Price, J1
Brady, P1
Hargreaves, O1
Harrison, P1
Slater, A1
Tiwari, A1
Nicolson, PLR1
Connolly, DL1
Kirchhof, P1
Kalia, N1
Jandrot-Perrus, M1
Mangin, PH1
Watson, SP1
Thomas, MR1
Zhang, Y1
Wang, S1
Qi, D1
Wang, X2
Li, M1
Zhu, Z1
Cheng, Q1
Hu, D1
Gao, C1
McGhie, D1
Amos, D1
Elder, A1
Brieger, D3
Lowe, HC1
Xiu, WJ1
Yang, HT1
Zheng, YY1
Ma, YT1
Xie, X1
de Castro, RL1
de Alcantara Lima, N1
da Costa Lino, DO1
Bannon, SF1
Gibson, CM2
Kumar, V1
Gopalakrishnan, L1
Singh, P1
Guo, J1
Kazziha, S1
Devireddy, C1
Pinto, D1
Marshall, JJ1
Stouffer, GA1
Mavromatis, K1
Grip, L1
Bainey, KR1
Rossi, R1
Bagnacani, A1
Sgura, F1
Enrique Monopoli, D1
Coppi, F1
Talarico, M1
Rolando, C1
Boriani, G1
You, J1
Li, H1
Guo, W1
Li, J2
Gao, L1
Wang, Y1
Geng, L1
Wan, Q1
Zhang, Q1
Benetou, DR1
Varlamos, C1
Mpahara, A1
Alexopoulos, D2
Puram, RV1
Erdil, RM1
Weber, BN1
Knelson, EH1
Van Beuningen, AM1
Wallwork, R1
Gilyard, SN1
Curtis, BR1
Ranganathan, R1
Leaf, RK1
Malhotra, R1
Kereiakes, DJ1
Henry, TD1
DeMaria, AN1
Bentur, O1
Carlson, M1
Seng Yue, C1
Martin, LH1
Midkiff, J1
Mueller, M1
Meek, T1
Garza, D1
Coller, BS1
d'Entremont, MA1
Laferrière, C1
Bérubé, S1
Couture, ÉL1
Lepage, S1
Huynh, T1
Verreault-Julien, L1
Karzon, A1
Desgagnés, N1
Nguyen, M1
Kumar, A1
Huded, CP1
Zhou, L1
Krittanawong, C1
Young, LD1
Krishnaswamy, A1
Menon, V1
Lincoff, AM1
Ellis, SG1
Reed, GW1
Kapadia, SR1
Khot, UN1
Khan, N1
Moss, A1
Gorog, DA1
Nightingale, P1
Armesilla, A1
Smallwood, A1
Munir, S1
Khogali, S1
Wrigley, B1
Cotton, JM1
Çınar, T1
Karabağ, Y1
Rencuzogullari, İ1
Cağdaş, M1
Wang, N1
Zhang, M2
Su, H1
Huang, Z1
Lin, Y1
Zeymer, U2
Leiva, O1
Hohnloser, SH1
Steg, PG2
Oldgren, J1
Nickenig, G1
Gabor Kiss, R1
Ongen, Z1
Navarro Estrada, J1
Oude Ophuis, T1
Lip, GYH1
Nordaby, M1
Miede, C1
Ten Berg, JM2
Cannon, CP2
Hochholzer, W1
Valina, CM1
Corbett, SJ1
Ftouh, S1
Lewis, S1
Lovibond, K1
Guedeney, P1
Collet, JP1
Lee, SJ1
Cho, JY1
Kim, BK1
Yun, KH1
Suh, Y1
Cho, YH1
Kim, YH1
Her, AY1
Cho, S1
Jeon, DW1
Yoo, SY1
Cho, DK1
Hong, BK1
Kwon, HM1
Hong, SJ1
Ahn, CM1
Shin, DH1
Nam, CM1
Kim, JS1
Ko, YG1
Choi, D1
Hong, MK1
Jang, Y1
Clarkson, SA1
Heindl, B1
Cai, A1
Beasley, M1
Dillon, C1
Limdi, N1
Brown, TM1
Çamlı, E1
Verdiyev, H1
Babayiğit, E1
Kurt, E1
Ulus, T1
Sanchez, F1
Boasi, V1
Vercellino, M1
Tacchi, C1
Cannarile, P1
Pingelli, N1
Perri, D1
Gomez, L1
Cattunar, S1
Mascelli, G1
Ferlini, M1
Leonardi, S2
Mandurino Mirizzi, A1
Montalto, C1
Crimi, G1
Repetto, A1
Marinoni, B1
Somaschini, A1
Ferrario, M1
Klersy, C1
Oltrona Visconti, L1
Tang, X1
Liu, L2
Yang, J1
Gao, Z1
Zhao, X1
Qiao, S1
Gao, R1
Yuan, J1
Yang, Y1
Elliott, JM1
Wang, TK1
Gamble, GD1
Williams, MJ1
Matsis, P1
Troughton, R1
Hamer, A1
Devlin, G1
Mann, S1
Richards, M1
French, JK1
White, HD1
Ellis, CJ1
Jang, HJ1
Park, SD1
Park, HW2
Suh, J1
Oh, PC1
Moon, J1
Lee, K1
Kang, WC1
Kwon, SW1
Kim, TH1
Forno, D1
Ferro, S1
Chinaglia, A1
Shavadia, J1
Welsh, R1
Gershlick, A1
Zheng, Y1
Huber, K3
Halvorsen, S1
Van de Werf, F1
Armstrong, PW1
Aitmokhtar, O1
Paganelli, F1
Benamara, S1
Azaza, A1
Bonello, L1
Hamza, O1
Seddiki, S1
Benathmane, T1
Saidane, M1
Bouzid, A1
Kara, M1
Sik, A1
Azzouz, A1
Harbi, F1
Monsuez, JJ1
Benkhedda, S1
Arous, S1
Haboub, M1
El Ghali Benouna, M1
Bentaoune, T1
Habbal, R1
Liu, Y1
Liu, H1
Hao, Y1
Hao, Z1
Geng, G1
Han, W1
Chen, Q1
Wang, D1
Jia, K1
Zhou, Y1
Shiran, A1
Adawi, S1
Rubinshtein, R1
Bardicef, M1
Gutterman, E1
van 't Hof, A1
Hamm, CW1
Lapostolle, F1
Lassen, JF1
Goodman, SG2
Bolognese, L1
Cequier, A2
Chettibi, M1
Hammett, CJ1
Janzon, M1
Merkely, B1
Storey, RF1
Cantor, WJ1
Tsatsaris, A1
Kerneis, M1
Diallo, A1
Vicaut, E1
Montalescot, G2
Ielasi, A1
Campo, G1
Rapetto, C1
Varricchio, A1
Cortese, B1
Brugaletta, S1
Geraci, S1
Vicinelli, P1
Scotto di Uccio, F1
Secco, GG1
Poli, A1
Nicolini, E1
Ishida, K1
Latib, A1
Tespili, M1
Yudi, MB1
Farouque, O1
Andrianopoulos, N1
Ajani, AE1
Brennan, A1
Lefkovits, J1
Reid, CM1
Chan, W1
Duffy, SJ1
Clark, DJ1
Giustino, G1
Mehran, R2
Dangas, GD1
Kirtane, AJ2
Redfors, B1
Généreux, P2
Brener, SJ1
Prats, J1
Pocock, SJ2
Deliargyris, EN1
Stone, GW2
Asher, E1
Tal, S1
Mazin, I1
Abu-Much, A1
Sabbag, A1
Katz, M1
Regev, E1
Chernomordik, F1
Guetta, V1
Segev, A1
Elian, D1
Barbash, I1
Fefer, P1
Narodistky, M1
Beigel, R1
Matetzky, S1
Sadjadieh, G1
Engstrøm, T1
Helqvist, S1
Høfsten, DE1
Pedersen, F1
Laursen, PN1
Nepper-Christensen, L1
Clemmensen, P1
Møller-Helgestad, OK1
Sørensen, R1
Ravkilde, J1
Terkelsen, CJ1
Jørgensen, E1
Saunamäki, K1
Tilsted, HH1
Kelbæk, H1
Holmvang, L1
Udell, JA1
Fonarow, GC1
Maddox, TM1
Frank Peacock, W1
Laskey, WK1
Grau-Sepulveda, MV1
Smith, EE1
Hernandez, AF1
Peterson, ED1
Spiezia, L1
Al Mamary, A1
Campello, E1
Piazza, D1
Maggiolo, S1
Dalla Valle, F1
Napodano, M1
Simioni, P1
Lin, TT1
Lai, HY1
Chan, KA1
Yang, YY1
Lai, CL1
Lai, MS1
Palmer, S1
Layland, J1
Adams, H1
Ashokkumar, S1
Williams, PD2
Judkins, C1
La Gerche, A1
Burns, AT1
Whitbourn, RJ1
MacIsaac, AI1
Wilson, AM1
Somuncu, MU2
Demir, AR2
Karakurt, H2
Serbest, NG1
Kalayci, B1
Bulut, U1
Karakurt, ST2
Lee, Y1
Park, HC1
Shin, J1
Weingärtner, O1
Schulze, PC1
Möbius-Winkler, S1
Filgueiras Filho, NM1
Feitosa Filho, GS1
Solla, DJF1
Argôlo, FC1
Guimarães, PO1
Paiva Filho, IM1
Carvalho, LGM1
Teixeira, LS1
Rios, MNO1
Câmara, SF1
Novais, VO1
Barbosa, LS1
Ballalai, CS1
De Lúcia, CV1
Granger, CB2
Newby, LK1
Lopes, RD1
Dimitroulis, D1
Golabkesh, M1
Naguib, D1
Knoop, B1
Dannenberg, L1
Helten, C1
Pöhl, M1
Jung, C1
Kelm, M1
Zeus, T1
Polzin, A1
Aliprandi-Costa, B1
Morgan, L1
Snell, LC1
D Souza, M1
Kritharides, L1
French, J1
Ranasinghe, I1
Gibler, WB1
Racadio, JM1
Hirsch, AL1
Roat, TW1
Leroux, E1
Houser, C1
Tabas, JA1
Mattu, A1
Brady, W1
Davis, JE1
Yu, HR1
Wei, YY1
Ma, JG1
Geng, XY1
Geraiely, B1
Poorhosseini, H1
Sadeghian, S1
Sattarzadeh Badkoubeh, R1
Mortazavi, SH1
Karabag, T1
Jackson, M1
Callaghan, S1
Stapleton, J1
Bolton, S1
Austin, D1
Muir, DF1
Sutton, AGC1
Wright, RA1
Hall, JA1
Carter, J1
de Belder, MA1
Swanson, N1
D'Ascenzo, F1
Bertaina, M1
Fioravanti, F1
Bongiovanni, F1
Raposeiras-Roubin, S1
Abu-Assi, E1
Kinnaird, T1
Ariza-Solé, A1
Manzano-Fernández, S1
Templin, C1
Velicki, L1
Xanthopoulou, I1
Rognoni, A1
Boccuzzi, G1
Omedè, P1
Montabone, A1
Taha, S1
Durante, A1
Gili, S1
Magnani, G1
Autelli, M1
Grosso, A1
Blanco, PF1
Garay, A1
Quadri, G1
Varbella, F1
Queija, BC1
Paz, RC1
Fernández, MC1
Pousa, IM1
Gallo, D1
Morbiducci, U1
Dominguez-Rodriguez, A1
Valdés, M1
Iñiguez-Romo, A1
Gaita, F1
Rinaldi, M1
Lüscher, TF1
Altıntaş, B1
Altındağ, R1
Bilge, Ö1
Baysal, E1
Öztürk, Ö1
Yaylak, B1
Ede, H1
Karahan, MZ1
Burak, C1
Tanboğa, İH1
Venkatason, P1
Zubairi, YZ1
Wan Ahmad, WA1
Hafidz, MI1
Ismail, MD1
Hadi, MF1
Zuhdi, ASM1
Iwańczyk, S1
Skorupski, W1
Grygier, M1
Sikora, T1
Araszkiewicz, A2
Lesiak, M1
Howard, I1
Castle, N1
Al Shaikh, L1
Owen, R1
Bruggmann, C1
Iglesias, JF1
Gex-Fabry, M1
Fesselet, R1
Vogt, P1
Sadeghipour, F1
Voirol, P1
Tscharre, M1
Farhan, S1
Bruno, V1
Rohla, M1
Egger, F1
Weiss, TW1
Hübl, W1
Willheim, M1
Wojta, J1
Geppert, A1
Freynhofer, MK1
Madhavan, MV1
Xu, K1
Witzenbichler, B1
Sabatine, MS1
Vergallo, R1
Aguirre, AD1
Abtahian, F1
Minami, Y1
Soeda, T1
Chatzizisis, YS1
Croce, K1
Jang, IK1
Radovanovic, D1
Maurer, L1
Bertel, O1
Witassek, F1
Urban, P1
Stauffer, JC1
Pedrazzini, G1
Erne, P1
Hu, S1
Yu, Y1
Yan, XF1
Jiang, LX1
Prech, M1
Bartela, E1
Janus, M1
Jeremicz, I1
Urbanska, L1
Pyda, M1
Grajek, S1
Dillinger, JG1
Saeed, A1
Spagnoli, V1
Sollier, CB1
Sideris, G1
Silberman, SM1
Voicu, S1
Drouet, L1
Henry, P1
Samoš, M2
Fedor, M2
Kovář, F2
Galajda, P2
Bolek, T2
Stančiaková, L2
Fedorová, J1
Staško, J2
Kubisz, P2
Mokáň, M2
Takahashi, T1
Okayama, H1
Matsuda, K1
Yamamoto, T1
Hosokawa, S1
Kosaki, T1
Kawamura, G1
Shigematsu, T1
Kinoshita, M1
Kawada, Y1
Hiasa, G1
Yamada, T1
Kazatani, Y1
Makam, RC1
Erskine, N1
McManus, DD1
Lessard, D1
Gore, JM1
Yarzebski, J1
Goldberg, RJ1
Liang, JJ1
Fenstad, ER1
Janish, CD1
Sinak, LJ1
Park, Y1
Tantry, US1
Koh, JS1
Ahn, JH1
Kang, MG1
Kim, KH1
Jang, JY1
Park, JR1
Hwang, SJ1
Park, KS1
Kwak, CH1
Hwang, JY1
Gurbel, PA1
Jeong, YH1
Oualim, S1
Elharda, CA1
Benzeroual, D1
Hattaoui, ME1
Duraj, L1
Šimonová, R1
Rossini, R1
Iorio, A1
Pozzi, R1
Musumeci, G1
Lettieri, C1
Bossi, I1
Colombo, P1
Rigattieri, S1
Dossena, C1
Anzuini, A1
Capodanno, D1
Senni, M1
Angiolillo, DJ1
Nicolau, JC1
Requena, G1
Maguire, A1
Blankenberg, S1
Chen, JY1
Grieve, R1
Simon, T1
Yasuda, S1
Vega, AM1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Characteristics and Clinical Outcomes of Acute Myocardial Infarction: A Prospective Cohort Study[NCT02737956]5,000 participants (Actual)Observational2016-06-01Completed
A Randomized Trial Evaluating Low-Dose IntraCoronary AdjunctivE Tenecteplase During Primary PCI for ST-Elevation Myocardial Infarction (ICE T)[NCT00604695]Phase 240 participants (Actual)Interventional2008-07-31Completed
A Randomized Phase 1 Dose-Escalation Study in Healthy Volunteers and Subjects on Aspirin With Stable Coronary Artery Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RUC-4[NCT03844191]Phase 144 participants (Actual)Interventional2019-02-18Completed
[NCT02494895]Phase 43,056 participants (Anticipated)Interventional2015-08-01Recruiting
STREAM (Strategic Reperfusion Early After Myocardial Infarction). Comparison of the Efficacy and Safety of a Strategy of Early Fibrinolytic Treatment With Tenecteplase and Additional Antiplatelet and Antithrombin Therapy Followed by Catheterisation Within[NCT00623623]Phase 31,899 participants (Actual)Interventional2008-03-01Completed
A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry[NCT02601781]Phase 4500 participants (Actual)Interventional2015-10-31Active, not recruiting
Chewing Versus Traditional Oral Administration of Ticagrelor in ST-elevation Myocardial Infarction Patients - A Platelet Reactivity Study[NCT02725099]Phase 450 participants (Actual)Interventional2016-05-31Completed
National Registry of Acute Myocardial Infarction in Switzerland[NCT01305785]60,000 participants (Anticipated)Observational1997-01-31Recruiting
The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction[NCT01624883]18,000 participants (Actual)Observational2012-04-30Completed
Aspirin DesensitizAtion in PatienTs With Coronary artEry Disease: Results of a Multi Center Registry: the ADAPTED Registry[NCT02848339]330 participants (Actual)Observational [Patient Registry]2010-05-31Completed
TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients[NCT01866904]9,284 participants (Actual)Observational2013-06-19Terminated (stopped due to Study was terminated in order to secure the data quality of the study in terms of follow-up rates and data completeness.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Measurements of Flow Velocity in the Culprit Artery in Terms of Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC)

Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) in the culprit artery (NCT00604695)
Timeframe: Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug

InterventionCorrected TIMI Frame Count (cTFC) (Median)
Active Treatment26
Placebo Control14

Number of Patients With Decrease in Thrombus Grade in the Culprit Artery Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention

(NCT00604695)
Timeframe: Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention

Interventionparticipants (Number)
Active Treatment7
Placebo Control2

Number of Patients With Hyperemic Flow in the Culprit Artery. That is Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of Less Than 14

Corrected Thrombolysis In Myocardial Infarction (TIMI) Frame Count (cTFC) of less than 14 (NCT00604695)
Timeframe: Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug

Interventionparticipants (Number)
Active Treatment1
Placebo Control5

Number of Patients With Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the Territory of the Culprit Artery Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug

Thrombolysis In Myocardial Infarction (TIMI) Myocardial Perfusion Grade (TMPG) of 2 or 3 in the territory of the culprit artery (NCT00604695)
Timeframe: Following Primary Percutaneous Coronary Intervention Prior to Second Bolus of the Study Drug

Interventionparticipants (Number)
Active Treatment8
Placebo Control8

Percent Diameter Stenosis of the Culprit Lesion Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention

(NCT00604695)
Timeframe: Following the First Bolus of Study Drug Prior to Primary Percutaneous Coronary Intervention

InterventionPercent diameter stenosis (Median)
Active Treatment100
Placebo Control100

Safety Endpoint: Number of Deaths

(NCT00604695)
Timeframe: Through 30days following primary percutaneous coronary intervention

Interventionparticipants (Number)
Active Treatment1
Placebo Control0

Safety Endpoint: Number of Patients Who Developed Cardiac Arrhythmias

(NCT00604695)
Timeframe: Through 30days following primary percutaneous coronary intervention

Interventionparticipants (Number)
Active Treatment1
Placebo Control2

Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minimal Bleeding

(NCT00604695)
Timeframe: Through 30days following primary percutaneous coronary intervention

Interventionparticipants (Number)
Active Treatment4
Placebo Control2

Safety Endpoint: Number of Patients Who Developed Thrombolysis In Myocardial Infarction (TIMI) Minor Bleeding

(NCT00604695)
Timeframe: Through 30days following PPCI

Interventionparticipants (Number)
Active Treatment1
Placebo Control0

Number of Patients With All Cause Death and Non-fatal Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and non-fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)50
Primary PCI (Group B)43

Number of Patients With All Cause Death and Shock

This is a key secondary endpoint. The number of observed patients with all cause death and shock within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)59
Primary PCI (Group B)73

Number of Patients With All Cause Death and Shock and CHF

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)100
Primary PCI (Group B)123

Number of Patients With All Cause Death and Shock and CHF and Reinfarction and Disabling Stroke

This is a key secondary endpoint. The number of observed patients with all cause death and shock and CHF and reinfarction and disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)117
Primary PCI (Group B)135

Number of Patients With All Cause Death and Shock and Reinfarction

This is a key secondary endpoint. The number of observed patients with all cause death and shock and reinfarction within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)77
Primary PCI (Group B)85

Number of Patients With All Cause Mortality

This is a key secondary endpoint. The number of observed patients with all cause mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)43
Primary PCI (Group B)42

Number of Patients With All-cause Mortality, Cardiogenic Shock, Congestive Heart Failure and Recurrent Myocardial Infarction Within 30 Days for FAS.

The number of observed patients with all-cause mortality, cardiogenic shock, congestive heart failure (CHF) and recurrent myocardial infarction within 30 days was reported for full analysis set (FAS). (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)116
Primary PCI (Group B)135

Number of Patients With Cardiac Mortality

This is a key secondary endpoint. The number of observed patients with cardiac mortality within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)31
Primary PCI (Group B)32

Number of Patients With Cardiogenic Shock

This is a key secondary endpoint. The number of observed patients with cardiogenic shock within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)41
Primary PCI (Group B)56

Number of Patients With Congestive Heart Failure (CHF)

This is a key secondary endpoint. The number of observed patients with congestive heart failure (CHF) within 30 days was reported. (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)57
Primary PCI (Group B)72

Number of Patients With Intracranial Haemorrhage

This is a key secondary endpoint. The number of observed patients with intracranial haemorrhage within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)9
Primary PCI (Group B)2

Number of Patients With Ischaemic Stroke

This is a key secondary endpoint. The number of observed patients with ischaemic stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)6
Primary PCI (Group B)3

Number of Patients With Major Non-intracranial Bleeds Including Blood Transfusions

This is a key secondary endpoint. The number of observed patients with major non-intracranial bleeds including blood transfusions within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)61
Primary PCI (Group B)45

Number of Patients With Minor Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with minor non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)206
Primary PCI (Group B)191

Number of Patients With Recurrent Myocardial Infarction (Reinfarction)

This is a key secondary endpoint. The number of observed patients with recurrent myocardial infarction (reinfarction) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)23
Primary PCI (Group B)21

Number of Patients With Rehospitalisation for Cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)45
Primary PCI (Group B)41

Number of Patients With Rehospitalisation for Non-cardiac Reasons

This is a key secondary endpoint. The number of observed patients with rehospitalisation for non-cardiac reasons within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)19
Primary PCI (Group B)11

Number of Patients With Serious Repeat Target Vessel Revascularization

This is a key secondary endpoint. The number of observed patients with serious repeat target vessel revascularization within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)1
Primary PCI (Group B)2

Number of Patients With Serious Resuscitated Ventricular Fibrillation

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)32
Primary PCI (Group B)38

Number of Patients With Serious Resuscitated Ventricular Fibrillation in Association With Invasive Procedures

This is a key secondary endpoint. The number of observed patients with serious resuscitated ventricular fibrillation in association with invasive procedures (occurring at any time during catheterisation or urgent/elective PCI) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)10
Primary PCI (Group B)29

Number of Patients With Total Disabling Stroke

This is a key secondary endpoint. The number of observed patients with total disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)2
Primary PCI (Group B)0

Number of Patients With Total Fatal Stroke

This is a key secondary endpoint. The number of observed patients with total fatal stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)7
Primary PCI (Group B)4

Number of Patients With Total Non-disabling Stroke

This is a key secondary endpoint. The number of observed patients with total non-disabling stroke within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)8
Primary PCI (Group B)1

Number of Patients With Total Non-intracranial Bleeds

This is a key secondary endpoint. The number of observed patients with total non-intracranial bleeds within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)267
Primary PCI (Group B)236

Number of Patients With Total Stroke (All Types)

This is a key secondary endpoint. The number of observed patients with total stroke (all types) within 30 days was reported (NCT00623623)
Timeframe: 30 days

InterventionParticipants (Count of Participants)
Tenecteplase (Group A)15
Primary PCI (Group B)5

Reviews

6 reviews available for aspirin and ST Elevated Myocardial Infarction

ArticleYear
Do We Really Need Aspirin Loading for STEMI?
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:6

    Topics: Animals; Aspirin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Morphine Derivatives; Percutaneous

2022
Effectiveness and Safety of P2Y12 Inhibitor Pretreatment for Primary PCI in STEMI: Systematic Review and Meta-analysis.
    Journal of cardiovascular pharmacology, 2023, 10-01, Volume: 82, Issue:4

    Topics: Aspirin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inh

2023
Double or Triple Antithrombotic Treatment in Atrial Fibrillation Patients with Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2021, Volume: 21, Issue:1

    Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Myocardial Infarction; Percut

2021
Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management.
    Thrombosis and haemostasis, 2021, Volume: 121, Issue:7

    Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Blood C

2021
Continuum of Care for Acute Coronary Syndrome: Optimizing Treatment for ST-Elevation Myocardial Infarction and Non-St-Elevation Acute Coronary Syndrome.
    Critical pathways in cardiology, 2018, Volume: 17, Issue:3

    Topics: Acute Coronary Syndrome; Aftercare; Aspirin; Cardiac Catheterization; Continuity of Patient Care; Co

2018
Oral dual antiplatelet therapy: what have we learnt from recent trials?
    European heart journal, 2016, Jan-21, Volume: 37, Issue:4

    Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Drug Therapy, Combination; Drug-Eluting Sten

2016

Trials

14 trials available for aspirin and ST Elevated Myocardial Infarction

ArticleYear
Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'targe
    Open heart, 2022, Volume: 9, Issue:2

    Topics: Acute Coronary Syndrome; Adolescent; Aspirin; Clopidogrel; Cohort Studies; Dinucleoside Phosphates;

2022
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitor

2023
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitor

2023
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitor

2023
Effects of intravenous lysine acetylsalicylate versus oral aspirin on platelet responsiveness in patients with ST-segment elevation myocardial infarction: the ECCLIPSE-STEMI trial.
    Journal of thrombosis and thrombolysis, 2023, Volume: 55, Issue:2

    Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitor

2023
Feasibility and Safety of Low-Dose Intra-Coronary Tenecteplase During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (ICE T-TIMI 49).
    The American journal of cardiology, 2020, 02-15, Volume: 125, Issue:4

    Topics: Aspirin; Clopidogrel; Combined Modality Therapy; Coronary Angiography; Drug Therapy, Combination; Fe

2020
Platelet function testing guided antiplatelet therapy reduces cardiovascular events in Chinese patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: The PATROL study.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2020, Volume: 95 Suppl 1

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; China; Clopidogrel; Drug Substi

2020
First Human Use of RUC-4: A Nonactivating Second-Generation Small-Molecule Platelet Glycoprotein IIb/IIIa (Integrin αIIbβ3) Inhibitor Designed for Subcutaneous Point-of-Care Treatment of ST-Segment-Elevation Myocardial Infarction.
    Journal of the American Heart Association, 2020, Volume: 9, Issue:17

    Topics: Adult; Aged; Aspirin; Case-Control Studies; Coronary Artery Disease; Female; Humans; Injections, Sub

2020
Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial.
    EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2021, Aug-27, Volume: 17, Issue:6

    Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Coronary Artery Disease; Dabigatran; Drug Therapy, Com

2021
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
    Kardiologia polska, 2017, Volume: 75, Issue:9

    Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy,

2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial.
    European heart journal. Acute cardiovascular care, 2019, Volume: 8, Issue:3

    Topics: Aged; Aspirin; Coronary Angiography; Coronary Circulation; Coronary Vessels; Double-Blind Method; Dr

2019
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.
    Journal of the American College of Cardiology, 2017, Oct-10, Volume: 70, Issue:15

    Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Cor

2017
Effect of Chewing vs Swallowing Ticagrelor on Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction: A Randomized Clinical Trial.
    JAMA cardiology, 2017, 12-01, Volume: 2, Issue:12

    Topics: Administration, Oral; Aged; Aspirin; Deglutition; Drug Therapy, Combination; Feasibility Studies; Fe

2017
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018, Volume: 24, Issue:8

    Topics: Adult; Aspirin; Carotid Artery Diseases; Carotid Intima-Media Thickness; Drug Resistance; Female; Hu

2018
ST-Elevation Acute Myocardial Infarction in Australia-Temporal Trends in Patient Management and Outcomes 1999-2016.
    Heart, lung & circulation, 2019, Volume: 28, Issue:7

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Australia; Female; Hospital Mortality; Humans; Hydrox

2019
Beneficial effects of combined administration of Clopidogrel and Aspirin on the levels of proinflammatory cytokines, cardiac function, and prognosis in ST-segment elevation myocardial infarction: A comparative study.
    Medicine, 2018, Volume: 97, Issue:45

    Topics: Aged; Aspirin; Clopidogrel; Cytokines; Drug Therapy, Combination; Female; Heart; Humans; Male; Middl

2018
Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial.
    European heart journal. Acute cardiovascular care, 2017, Volume: 6, Issue:7

    Topics: Aged; Antithrombins; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combinati

2017

Other Studies

73 other studies available for aspirin and ST Elevated Myocardial Infarction

ArticleYear
The timing of administering aspirin and nitroglycerin in patients with STEMI ECG changes alter patient outcome.
    BMC emergency medicine, 2021, 11-17, Volume: 21, Issue:1

    Topics: Aspirin; Electrocardiography; Humans; Nitroglycerin; Retrospective Studies; ST Elevation Myocardial

2021
[Management of ST-elevation myocardial infarction in a patient with aspirin hypersensitivity without oral P2Y12 inhibitors].
    Giornale italiano di cardiologia (2006), 2022, Volume: 23, Issue:1

    Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y

2022
Is Aspirin Loading Before Primary Percutaneous Coronary Intervention for Patients with ST-Elevation Myocardial Infarction Necessary?
    Cardiovascular drugs and therapy, 2022, Volume: 36, Issue:6

    Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation M

2022
Effect of prehospital treatment in STEMI patients undergoing primary PCI.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2022, Volume: 99, Issue:5

    Topics: Aspirin; Emergency Medical Services; Fibrinolytic Agents; Humans; Myocardial Infarction; Percutaneou

2022
Effectiveness and safety of P2Y12 inhibitors in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a nationwide registry-based study.
    European heart journal. Acute cardiovascular care, 2022, Sep-29, Volume: 11, Issue:9

    Topics: Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation I

2022
Impact of QRS Duration on Non-ST-Segment Elevation Myocardial Infarction (from a National Registry).
    The American journal of cardiology, 2022, 11-15, Volume: 183

    Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Humans; M

2022
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
    The American journal of emergency medicine, 2023, Volume: 65

    Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou

2023
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
    The American journal of emergency medicine, 2023, Volume: 65

    Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou

2023
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
    The American journal of emergency medicine, 2023, Volume: 65

    Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou

2023
Aspirin use in ST-elevation myocardial infarction (STEMI) patients transported by emergency medical services (EMS).
    The American journal of emergency medicine, 2023, Volume: 65

    Topics: Aspirin; Electrocardiography; Emergency Medical Services; Humans; Myocardial Infarction; Percutaneou

2023
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
    International journal of clinical pharmacy, 2023, Volume: 45, Issue:2

    Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Ag

2023
The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study.
    Journal of cardiovascular pharmacology, 2023, 08-01, Volume: 82, Issue:2

    Topics: Acute Coronary Syndrome; Aspirin; East Asian People; Hemorrhage; Humans; Percutaneous Coronary Inter

2023
Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Health technology assessment (Winchester, England), 2023, Volume: 27, Issue:8

    Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cohort Studies; Humans; Platelet Aggregation Inhibito

2023
Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
    Journal of thrombosis and haemostasis : JTH, 2023, Volume: 21, Issue:11

    Topics: Acute Coronary Syndrome; Animals; Aspirin; Fibrinolytic Agents; Humans; Mice; Plaque, Atheroscleroti

2023
Changes in process and outcome for ST elevation myocardial infarction in central China from 2011 to 2018.
    Chinese medical journal, 2023, Sep-20, Volume: 136, Issue:18

    Topics: Adrenergic beta-Antagonists; Aspirin; Cross-Sectional Studies; Female; Hospital Mortality; Humans; H

2023
Life after abciximab; what's next for intracoronary thrombus?
    Journal of thrombosis and thrombolysis, 2020, Volume: 49, Issue:1

    Topics: Abciximab; Aged; Aspirin; Coronary Thrombosis; Heparin; Humans; Male; Platelet Glycoprotein GPIIb-II

2020
Delayed PCI 12 Hours after the Onset of Symptoms Is Associated with Improved Outcomes for Patients with ST-Segment Elevation Myocardial Infarction: A Real-World Study.
    Journal of interventional cardiology, 2019, Volume: 2019

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; China; Clopidogrel; Female; Heparin, Low-Molecular-Weight;

2019
Concealed Wolff-Parkinson-White Syndrome revealed by acute coronary syndrome.
    Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2020, Volume: 25, Issue:5

    Topics: Acute Coronary Syndrome; Analgesics, Opioid; Aspirin; Clopidogrel; Drug-Eluting Stents; Electrocardi

2020
Effect on mortality of different routes of administration and loading dose of aspirin in patients with ST-segment elevation acute myocardial infarction treated with primary angioplasty.
    Coronary artery disease, 2020, Volume: 31, Issue:4

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Dose-Response Relationship, Dru

2020
Thrombocytopenia and Thromboses in Myocardial Infarction Associated with Eptifibatide-Dependent Activating Antiplatelet Antibodies.
    Thrombosis and haemostasis, 2020, Volume: 120, Issue:7

    Topics: Antigens, Human Platelet; Arginine; Aspirin; Autoantibodies; Combined Modality Therapy; Coronary Thr

2020
The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2021, Volume: 97, Issue:4

    Topics: Aspirin; Heparin; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggreg

2021
Implementation of a Comprehensive ST-Elevation Myocardial Infarction Protocol Improves Mortality Among Patients With ST-Elevation Myocardial Infarction and Cardiogenic Shock.
    The American journal of cardiology, 2020, 11-01, Volume: 134

    Topics: Aged; Anticoagulants; Aspirin; Checklist; Clinical Protocols; Disease Management; Emergency Service,

2020
Aspirin related platelet reactivity as a determinant of ten year survival in high risk non-ST segment elevation myocardial infarction (NSTEMI) patients.
    Thrombosis research, 2020, Volume: 196

    Topics: Aspirin; Blood Platelets; Electrocardiography; Hospital Mortality; Humans; Myocardial Infarction; No

2020
Microfistulas Causing Diverse Regional Ischemia: Consecutive Inferior and Lateral ST-Elevation Myocardial Infarction.
    Archives of Iranian medicine, 2020, 10-01, Volume: 23, Issue:10

    Topics: Aspirin; Coronary Angiography; Coronary Vessel Anomalies; Electrocardiography; Humans; Male; Metopro

2020
Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic.
    The Journal of international medical research, 2020, Volume: 48, Issue:10

    Topics: Aged; Aspirin; Clopidogrel; Coronavirus Infections; COVID-19; Female; Fibrinolysis; Fibrinolytic Age

2020
Antiplatelet therapy for STEMI: Hit it hard and early?
    International journal of cardiology, 2021, 04-01, Volume: 328

    Topics: Aspirin; Blood Platelets; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitor

2021
Acute coronary syndromes: summary of updated NICE guidance.
    BMJ (Clinical research ed.), 2021, 01-15, Volume: 372

    Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Cardiac Rehabilitation; Clopidogrel; Combined Mo

2021
Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction.
    JACC. Cardiovascular interventions, 2021, 02-22, Volume: 14, Issue:4

    Topics: Aspirin; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation M

2021
Outcomes of Individuals With and Without Heart Failure Presenting With Acute Coronary Syndrome.
    The American journal of cardiology, 2021, 06-01, Volume: 148

    Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Case-Control Studies; Clopidogrel; Diabete

2021
How to manage aspirin hypersensitivity in a patient with ST-segment elevation myocardial infarction and a drug-eluting stent.
    Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2021, Volume: 49, Issue:2

    Topics: Aged; Aspirin; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Drug Hype

2021
Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry.
    BMC cardiovascular disorders, 2021, 03-18, Volume: 21, Issue:1

    Topics: Aged; Aspirin; Clinical Decision-Making; Clinical Trials as Topic; Drug Administration Schedule; Dua

2021
Oral aspirin or low dose of intravenous lysine acetylsalicylate in ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2021, 07-01, Volume: 22, Issue:7

    Topics: Administration, Oral; Aged; Aspirin; Coronary Care Units; Drug Monitoring; Female; Humans; Injection

2021
Evidence-based oral antiplatelet therapy among hospitalized Chinese patients with acute myocardial infarction: results from the Chinese acute myocardial infarction registry.
    BMC cardiovascular disorders, 2021, 06-14, Volume: 21, Issue:1

    Topics: Administration, Oral; Aged; Aspirin; China; Clopidogrel; Drug Utilization; Dual Anti-Platelet Therap

2021
A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012.
    The New Zealand medical journal, 2017, Apr-07, Volume: 130, Issue:1453

    Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Angiography; Drug Therapy

2017
Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.
    Drugs & aging, 2017, Volume: 34, Issue:6

    Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male;

2017
Characteristics, in-hospital management and outcome of late acute ST-elevation myocardial infarction presenters.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:8

    Topics: Acute Disease; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation

2017
Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM)
    Journal of the American Heart Association, 2016, 06-13, Volume: 5, Issue:6

    Topics: Aged; Aspirin; Catheterization, Peripheral; Clopidogrel; Coronary Angiography; Enoxaparin; Female; F

2016
Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
    Archives of cardiovascular diseases, 2017, Volume: 110, Issue:11

    Topics: Aged; Area Under Curve; Aspirin; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Ang

2017
Ischemic stroke complicating thrombolytic therapy with tenecteplase for ST elevation myocardial infarction: two case reports.
    Journal of medical case reports, 2017, Jun-11, Volume: 11, Issue:1

    Topics: Aged; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Heparin; Humans; Ischemic Atta

2017
Non-invasive management of post-partum spontaneous left main coronary artery dissection using cardiac computed tomography angiography.
    European heart journal. Cardiovascular Imaging, 2017, 10-01, Volume: 18, Issue:10

    Topics: Adult; Aspirin; Bisoprolol; Cesarean Section; Clopidogrel; Computed Tomography Angiography; Conserva

2017
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
    JACC. Cardiovascular interventions, 2017, 09-25, Volume: 10, Issue:18

    Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis;

2017
Pretreatment with dual antiplatelet therapy in patients with ST-elevation myocardial infarction.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2018, 08-01, Volume: 92, Issue:2

    Topics: Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans;

2018
Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy).
    The American journal of cardiology, 2018, 04-01, Volume: 121, Issue:7

    Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Aspirin; Creatinine; Female; Heparin; Hirudi

2018
Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry.
    Clinical cardiology, 2018, Volume: 41, Issue:6

    Topics: Acute Coronary Syndrome; Age Factors; Aged; American Heart Association; Aspirin; Chi-Square Distribu

2018
On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI).
    Scandinavian journal of clinical and laboratory investigation, 2018, Volume: 78, Issue:4

    Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Coronary Vessels; Demography; Fem

2018
Single and dual antiplatelet therapy in elderly patients of medically managed myocardial infarction.
    BMC geriatrics, 2018, 04-05, Volume: 18, Issue:1

    Topics: Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy, Combination; Electrocardiogra

2018
Measurement of microvascular function in patients presenting with thrombolysis for ST elevation myocardial infarction, and PCI for non-ST elevation myocardial infarction.
    Cardiovascular revascularization medicine : including molecular interventions, 2018, Volume: 19, Issue:8

    Topics: Aspirin; Cardiac Catheterization; Clopidogrel; Coronary Circulation; Coronary Vessels; Echocardiogra

2018
Clinical efficacy of aspirin with identification of intimal morphology by optical coherence tomography in preventing event recurrence in patients with vasospasm-induced acute coronary syndrome.
    The international journal of cardiovascular imaging, 2018, Volume: 34, Issue:11

    Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Coronary Vasospasm; Coronary Vessels;

2018
[Optical Coherence Tomography in ST-Elevation Myocardial Infarction].
    Deutsche medizinische Wochenschrift (1946), 2018, Volume: 113, Issue:13

    Topics: Aged, 80 and over; Aspirin; Coronary Angiography; Coronary Artery Disease; Diagnosis, Differential;

2018
Implementation of a Regional Network for ST-Segment-Elevation Myocardial Infarction (STEMI) Care and 30-Day Mortality in a Low- to Middle-Income City in Brazil: Findings From Salvador's STEMI Registry (RESISST).
    Journal of the American Heart Association, 2018, 07-06, Volume: 7, Issue:14

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2018
Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction.
    Journal of cardiovascular pharmacology, 2018, Volume: 72, Issue:4

    Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Germany; Hemorrhage; Humans; Male; Middle Aged; Pe

2018
Elderly Man With Chest Pressure.
    Annals of emergency medicine, 2018, Volume: 72, Issue:5

    Topics: Aged; Aspirin; Chest Pain; Dizziness; Electrocardiography; Emergency Service, Hospital; Humans; Male

2018
Are Prior Aspirin Users With ST-Elevation Myocardial Infarction at Increased Risk of Adverse Events and Worse Angiographic Features?
    Critical pathways in cardiology, 2018, Volume: 17, Issue:4

    Topics: Aspirin; Coronary Angiography; Disease Progression; Female; Follow-Up Studies; Humans; Iran; Male; M

2018
Long Term Cardiovascular Outcome Based on Aspirin and Clopidogrel Responsiveness Status in Young ST-Elevated Myocardial Infarction Patients.
    Arquivos brasileiros de cardiologia, 2019, Volume: 112, Issue:2

    Topics: Adult; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Female; Follow-Up Studies; Hu

2019
Rapid Aspirin Desensitization is Safe and Feasible in Patients With Stable and Unstable Coronary Artery Disease: A Single-Center Experience.
    Journal of cardiovascular pharmacology and therapeutics, 2019, Volume: 24, Issue:4

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Desensitization, Immunologic; Drug Hypers

2019
Long versus short dual antiplatelet therapy in acute coronary syndrome patients treated with prasugrel or ticagrelor and coronary revascularization: Insights from the RENAMI registry.
    European journal of preventive cardiology, 2020, Volume: 27, Issue:7

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Administration Schedule; Dual Anti-Platelet Therapy; Eu

2020
The effect of ticagrelor based dual antiplatelet therapy on development of late left ventricular thrombus after acute anterior ST elevation myocardial infarction.
    International journal of cardiology, 2019, 07-15, Volume: 287

    Topics: Aged; Anterior Wall Myocardial Infarction; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response

2019
In-hospital mortality of cardiogenic shock complicating ST-elevation myocardial infarction in Malaysia: a retrospective analysis of the Malaysian National Cardiovascular Database (NCVD) registry.
    BMJ open, 2019, 05-05, Volume: 9, Issue:5

    Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Databases, Factual; Female; Hospital Mortal

2019
Myocardial infarction with nonobstructive coronary arteries in a young woman: the key role of optical coherence tomography.
    Kardiologia polska, 2019, Aug-23, Volume: 77, Issue:7-8

    Topics: Abciximab; Adult; Aspirin; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Female; Huma

2019
Improving the prehospital management of ST elevation myocardial infarction: a national quality improvement initiative.
    BMJ open quality, 2019, Volume: 8, Issue:2

    Topics: Aspirin; Clopidogrel; Electrocardiography; Emergency Medical Services; Guideline Adherence; Humans;

2019
Long-Term Quality of Prescription for ST-Segment Elevation Myocardial Infarction (STEMI) Patients: A Real World 1-Year Follow-Up Study.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2020, Volume: 20, Issue:1

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2020
Impact of platelet turnover on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
    European journal of clinical investigation, 2019, Volume: 49, Issue:9

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Diseas

2019
Recurrent myocardial infarctions and premature coronary atherosclerosis in a 23-year-old man with antiphospholipid syndrome.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Coronary Angiography; Coronary Artery Disease; H

2016
Treatment and outcomes of patients with recurrent myocardial infarction: A prospective observational cohort study.
    Journal of cardiology, 2016, Volume: 68, Issue:6

    Topics: Age Factors; Aged; Aspirin; Cohort Studies; Comorbidity; Drug Utilization; Female; Guideline Adheren

2016
[ST-segment elevation myocardial infarction in the eastern urban China: from 2001 to 2011].
    Zhonghua xin xue guan bing za zhi, 2016, Apr-24, Volume: 44, Issue:4

    Topics: Aged; Aspirin; China; Clopidogrel; Female; Hospitalization; Hospitals; Humans; Logistic Models; Male

2016
Effect of a combination of antiplatelet and antithrombotic pretreatment on myocardial perfusion in patients with an acute ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention.
    Coronary artery disease, 2016, Volume: 27, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Clopidogrel; Coronary Angiography; Coronary Cir

2016
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
    Thrombosis research, 2016, Volume: 144

    Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido

2016
The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Clopidogrel; Diabetes Mellitus, Type

2016
Optical coherence tomography-based diagnosis in a patient with ST-elevation myocardial infarction and no obstructive coronary arteries.
    International journal of cardiology, 2016, Nov-15, Volume: 223

    Topics: Aspirin; Clinical Decision-Making; Coronary Angiography; Coronary Vessels; Diagnosis, Differential;

2016
Decade-Long Trends (2001 to 2011) in the Use of Evidence-Based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction.
    The American journal of cardiology, 2016, Dec-15, Volume: 118, Issue:12

    Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I

2016
Left ventricular non-compaction cardiomyopathy: Incidental diagnosis after ST-elevation myocardial infarction.
    Acute cardiac care, 2016, Volume: 18, Issue:1

    Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiomyopathy, Hypertrophic, Familial; Clopidogrel;

2016
Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial.
    Thrombosis and haemostasis, 2017, 05-03, Volume: 117, Issue:5

    Topics: Aged; Aspirin; Biomarkers; Blood Platelets; C-Reactive Protein; Chi-Square Distribution; Clopidogrel

2017
Pulmonary alveolar hemorrhage mimicking a pneumopathy: a rare complication of dual antiplatelet therapy for ST elevation myocardial infarction.
    The Pan African medical journal, 2016, Volume: 24

    Topics: Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; Lung Diseases; Middle A

2016
Monitoring the hemostasis with rotation thromboelastometry in patients with acute STEMI on dual antiplatelet therapy: First experiences.
    Medicine, 2017, Volume: 96, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Coronary Angiography; Female; Hemostasis

2017
Aspirin Desensitization in Patients With Coronary Artery Disease: Results of the Multicenter ADAPTED Registry (Aspirin Desensitization in Patients With Coronary Artery Disease).
    Circulation. Cardiovascular interventions, 2017, Volume: 10, Issue:2

    Topics: Acute Coronary Syndrome; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Desensitizati

2017
Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study.
    International journal of cardiology, 2017, Jun-01, Volume: 236

    Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Femal

2017